Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector

Area of Science:

• * Gene Therapy
• * Virology
• * Clinical Trials

Background:

• * Duchenne muscular dystrophy (DMD) requires efficient gene transfer for effective treatment.
• * Current gene therapy approaches face challenges with vector efficiency and immune responses.
• * Rational design of adeno-associated virus (AAV) vectors is crucial for improving gene delivery.

Purpose of the Study:

• * To evaluate the safety and tolerability of a rationally designed chimeric AAV capsid variant (AAV2.5) in a Phase I clinical trial for DMD.
• * To assess the gene transfer efficiency and immune response to the AAV2.5 vector in DMD patients.
• * To establish a foundation for customized AAV vector development for human gene transfer.

Main Methods:

• * A randomized, double-blind, placebo-controlled Phase I clinical study involving DMD boys.
• * Intramuscular injection of AAV2.5 vector into one bicep, with saline or AAV empty capsid control in the contralateral arm.
• * Detection of recombinant AAV genomes and assessment of cellular immune responses to the AAV2.5 capsid.

Main Results:

• * Recombinant AAV genomes were successfully detected in all treated patients, with up to 2.56 vector copies per diploid genome.
• * No cellular immune response was observed against the AAV2.5 capsid.
• * The AAV2.5 vector was found to be safe and well-tolerated in DMD patients.

Conclusions:

• * The rationally designed AAV2.5 vector is safe and well-tolerated for gene transfer in DMD.
• * This study validates the potential of customizing AAV vectors for specific clinical objectives, such as limb infusion gene delivery.
• * The findings support the development of next-generation viral delivery systems for human gene therapy applications.